Revenue Breakdown
Composition ()
No data
Revenue Streams
Immuron Ltd (IMRN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is HyperImmune Products, accounting for 100.0% of total sales, equivalent to AUD 1.22M. Other significant revenue streams include Travelan and Protectyn. Understanding this composition is critical for investors evaluating how IMRN navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Immuron Ltd maintains a gross margin of 66.52%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -70.88%, while the net margin is -62.31%. These profitability ratios, combined with a Return on Equity (ROE) of -52.77%, provide a clear picture of how effectively IMRN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IMRN competes directly with industry leaders such as BFRI and EDSA. With a market capitalization of $6.51M, it holds a significant position in the sector. When comparing efficiency, IMRN's gross margin of 66.52% stands against BFRI's 70.74% and EDSA's N/A. Such benchmarking helps identify whether Immuron Ltd is trading at a premium or discount relative to its financial performance.
